Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Multiple Sclerosis

Free Subscription 05.11.2018 1 AJNR Am J Neuroradiol 1 BMC Neurol 1 Eur Neurol 1 J Neuroimmunol 4 J Neurol 6 Mult Scler 6 Neurology 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJNR Am J Neuroradiol

1. SAADE C, Bou-Fakhredin R, Yousem DM, Asmar K, et al
   Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics.
   AJNR Am J Neuroradiol. 2018 Nov 1. pii: ajnr.A5773. doi: 10.3174/ajnr.A5773.
   PubMed     Text format     Abstract available
   
   

   
   BMC Neurol

2. VAKRAKOU AG, Tzanetakos D, Valsami S, Grigoriou E, et al
   A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
   BMC Neurol. 2018;18:178.
   PubMed     Text format     Abstract available
   
   

   
   Eur Neurol

3. GEBHARDT M, Kropp P, Hoffmann F, Zettl UK, et al
   Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study.
   Eur Neurol. 2018;80.
   PubMed     Text format     Abstract available
   
   

   
   J Neuroimmunol

4. SAFIZADEH B, Hoshyar R, Mehrpour M, Eftekhar M, et al
   The role of expression and activity of 15-Lipoxygenase isoforms and related cytokines in patients with Multiple Sclerosis and healthy controls.
   J Neuroimmunol. 2018;325:32-42.
   PubMed     Text format     Abstract available
   
   

   
   J Neurol

5. MALLUCCI G, Annovazzi P, Miante S, Torri-Clerici V, et al
   Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
   J Neurol. 2018;265:1850-1859.
   PubMed     Text format     Abstract available
   
   
6. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
   Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
   J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
   PubMed     Text format     Abstract available
   
   
7. ELLRICHMANN G, Bolz J, Peschke M, Duscha A, et al
   Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
   J Neurol. 2018 Oct 30. pii: 10.1007/s00415-018-9092.
   PubMed     Text format     Abstract available
   
   
8. SAEZ MS, Rojas JI, Lorenzon MV, Sanchez F, et al
   Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires.
   J Neurol. 2018 Nov 1. pii: 10.1007/s00415-018-9106.
   PubMed     Text format     Abstract available
   
   

   
   Mult Scler

9. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
   De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
   Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
   PubMed     Text format     Abstract available
   
   
10. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed     Text format    
    
    
11. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Text format     Abstract available
    
    
12. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Text format     Abstract available
    
    
13. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Text format     Abstract available
    
    
14. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Text format     Abstract available
    
    

    
    Neurology

15. LEWIS A, Galetta S
    Editors' note: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849.
    PubMed     Text format    
    
    
16. PROSCHMANN U, Akgun K, Ziemssen T
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849-850.
    PubMed     Text format    
    
    
17. SOTGIU S, Eusebi A, Begliuomini C, Guerini FR, et al
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:850.
    PubMed     Text format    
    
    
18. PORTACCIO E, Amato MP
    Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:851.
    PubMed     Text format    
    
    
19. SOLOMON AJ, Naismith RT, Cross AH
    Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.
    Neurology. 2018 Oct 31. pii: WNL.0000000000006583.
    PubMed     Text format     Abstract available
    
    
20. BROWNLEE WJ
    Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?
    Neurology. 2018 Oct 31. pii: WNL.0000000000006584.
    PubMed     Text format    
    
    

    
    PLoS One

21. RHEAD B, Brorson IS, Berge T, Adams C, et al
    Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.
    PLoS One. 2018;13:e0206511.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: